Examining the Clinical Implications of Emerging Disease-Specific Therapies
Courses
Meena B. Bansal, MD, FAASLD
Quentin M. Anstee, MBBS, PhD, FRCP
Elisabetta Bugianesi, MD, PhD
Entering a New Era in Metabolic Dysfunction-Associated Steatohepatitis: Examining the Clinical Implications of Emerging Disease-Specific Therapies
Credit Available: 1.00 AMA PRA Category 1 credit(s)
Course Director: Meena B. Bansal, MD, FAASLD
Course Faculty: Quentin M. Anstee, MBBS, PhD, FRCP, and Elisabetta Bugianesi, MD, PhD.
Presented at the International Liver Congress, EASL 2024, this activity will explore new innovations in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The recent approval of the first disease-specific therapy ushers in a new era for patient-centered care. Hear leading hepatologists from around the world consider the recent advancements in treatment through case-based discussions. Also, find out the best ways to identify patients who will benefit most in this new area of disease-specific care.
Presented at Digestive Disease Week 2024, DDW 2024
Meena B. Bansal, MD, FAASLD
Naim Alkhouri, MD, FAASLD
Mazen Noureddin, MD, MHSc
Entering a New Era in Metabolic Dysfunction-Associated Steatohepatitis: Examining the Clinical Implications of Emerging Disease-Specific Therapies
Credit Available: 1.25 AMA PRA Category 1 credit(s)
Course Director: Meena B. Bansal, MD, FAASLD
Course Faculty: Naim Alkhouri, MD, FAASLD and Mazen Noureddin, MD, MHSc
Presented at Digestive Disease Week, DDW 2024, this activity explores the latest clinical efficacy and safety data of approved and emerging disease-specific therapies for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Hepatology experts will discuss the mechanism of action of the first US Food and Drug Administration-approved thyroid hormone receptor-β (THR-β) agonist and examine case-based scenarios for optimizing pharmacologic management MASLD/MASH in this new treatment era. Considerations around disease staging will also be presented to ensure optimal patient management.